Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines;Endometriyal adenokanser hücre serilerinde GnRH analogları ve oktreotidin apoptozis ve hücre proliferasyonu üzerindeki etkileri

Journal of the Turkish German Gynecology Association

Volumn 11, Issue 3, 2010, Pages 131-136

  Öztürk, Harika Bodur ^a   Vural, Birol ^b   Çalhşkan, Eray ^b   Solakoǧlu, Seyhun ^c  

^a ACIBADEM HOSPITAL   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Cell proliferation; Endometrial cancer; Gonadotropin releasing hormone analogues; Octreotide

Indexed keywords

GANIRELIX; GONADORELIN DERIVATIVE; LEUPRORELIN; OCTREOTIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TEMPERATURE; INCUBATION TIME; NICK END LABELING;

EID: 78249281356     PISSN: 13090399     EISSN: 13090380     Source Type: Journal    
DOI: 10.5152/jtgga.2010.19     Document Type: Article

References (27)

1. Emons G, Heyl W. Hormonal treatment of endometrial cancer. J Cancer Res Clin Oncol 2000; 126: 619-23.
2. Latta E, Chapman WB. PTEN mutations and evolving concept in endometrial neoplasia. Curr Opin Obstet Gynecol 2002; 14: 59-65.
3. Assunção Guimarães C, Linden R. Programmed cell death. Apoptosis and alternative deathsytles. Eur J Biochem 2004; 271: 1638-50.
4. Arends MJ. Apoptosis in the endometrium. Histopathology 1999; 35: 174-8.
5. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Gonadotropin releasing hormone receptor in gynecologic tumors: frequent expression in adenocarsinoma histologic types. Cancer 1994; 74: 2555-61.
6. Völker P, Gründker C, Schmidt O, Schutz KD, Emons G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: Frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormonereleasing hormone analogues. Am J Obstet Gynecol 2002; 186: 171-9.
7. Jeon YT, Kim YB, Park SY, Kim JW, Park NH, Kang SB, et al. Gonadotropin- releasing hormone receptor expression in endometrial cancer. Int J Gynecol Pathol 2009; 28: 19-22.
8. Manni A, Santen R, Harvey H, Lipton A, Max D. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr Rev 1986; 7: 89-94.
9. Iversen P, Suciu S, Sylvester R, Christensen I, Denis L. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. Cancer 1990; 66: 1067-73.
10. Gallagher CJ, Oliver RT, Oram DH, Fowler CG, Blake PR, Mantell BS, et al. A new treatment for endometrial cancer with gonadotropin releasing hormone analogue. Br J Obstet Gynaecol 1991; 98: 1037-41.
11. Emons G, Ortmann O, Pahwa GS, Hackenberg R, Oberheuser F, Schultz KD. Intracellular action of gonadotropic and peptide hormones and the therapeutic value of GnRH agonist in ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992; 155: 31-8.
12. Huirne JA, Lambalk CB. Gonadotropin-releasing hormone receptor antagonist. New drug classes. Lancet 2001; 358: 1793-803.
13. Kleinman D, Douvdevani A, Schally AV, Levy J, Sharoni Y. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis. Am J Obstet Gynecol 1994; 170: 96-102.
14. Emons G, Muller V, Ortmann O, Schultz KD. Effect of LHRH analogues on mitogenic signal transduction in cancer cells. Steroid Biochem Mol Biol 1998; 65: 199-206.
15. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Presence of Gonadotropin-Releasing Hormone Receptor and its messenger ribonucleic acid in endometrial carsinoma and endometrium. Gynecol Oncol 1994; 55: 144-8.
16. Wu HM, Cheng JC, Wang HS, Huang HY, MacCalman CD, Leung PC. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha. Cancer Res. 2009; 69: 4202-8.
17. Park DW, Choi KC, MacCalman CD, Leung PC. Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase. Reprod Biol Endocrinol. 2009; 7: 81.
18. Emons G, Gründker C, Günthert AR, Westphalen S, Kavanagh J, Verschraegen C. GnRH antagonist in the treatment of gynecological and breast cancers. Endocrine Related Cancer 2003; 10: 291-9.
19. Gründker C, Günthert AR, Millar RP, Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002; 87: 1427-30.
20. Dahmoun M, Backstrom T, Boman K, Cajander S. Apoptosis, proliferation, and hormone receptors in endometrial carsinoma: Results depending on methods of analysis. Int J Oncol 2003; 22: 115-22.
21. Imai A, Takagi A, Horibe S, Takagi H.Tamaya T. Evidence For Tight Coupling of Gonadotropin-Releasing Hormone Receptor to Stimulated Fas Ligand Expession in Reproductive Tract Tumors: Possible Mechanism for Hormonal Control of Apoptotic Cell Death. J Clin Endocrinol Metab 1998; 83: 427-31.
22. Noci I, Coronnello M, Borri P, Borrani E, Giachi M, Chieffi O, et al. Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. Cancer Lett 2000; 150: 71-8.
23. Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD, Schally AV. High affinity bindign and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993; 77: 1458-64.
24. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factor and neoplasia Nature Reviews Cancer 2004; 4: 505-18.
25. Pollak MN, Schally AV. Mechanism of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998; 217: 143-52.
26. Schulz S, Schmitt J, Weise W. Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. Gynecol Oncol 2003; 89: 385-90.
27. Mishima M, Yano T, Jimbo H, Yano N, Morita Y, Yoshikawa H, et al. Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. Am J Obstet Gynecol 1999; 181: 583-90.